单孔腹腔镜子宫肌瘤剔除术的应用现状与临床价值

Application Status and Clinical Value of Single Port Laparoscopic Myomectomy

摘要: 子宫肌瘤是女性患者最常见的良性肿瘤，子宫肌瘤患者治疗方案的选择与其预后和生活质量密切相关。单孔腹腔镜子宫肌瘤剔除术(single port laparoscopic myomectomy，简称SPLM)作为一种新的微创手术方法，具有创伤小、复发快、美观无疤痕等优点，近年来备受关注。本文对SPLM的技术特点、适应证、禁忌证、临床效果等研究进行了总结和述评，并展望SPLM的发展前景。SPLM对于降低手术创伤、术后疼痛具有明显优势，但技术难点较多，安全可行性及远期复发性仍需更多循证医学证据。通过分析现有文献，继续进一步优化技术、规范适应证选择并加强术者培训，SPLM有望成为子宫肌瘤手术治疗的重要选项之一，为患者提供更个性化、人性化的治疗选择。

Abstract: Uterine fibroids represent the most prevalent benign tumors among female patients. The selection of treatment modalities for uterine fibroid patients is intricately linked to their prognosis and quality of life. Single-port laparoscopic myomectomy (SPLM), a novel minimally invasive surgical technique, has attracted substantial attention in recent years. This is attributable to its notable advantages, including minimal invasiveness, rapid recovery, and the ability to achieve cosmetically favorable, scar-less outcomes. This paper comprehensively summarizes and reviews the existing research regarding the technical features, indications, contraindications, and clinical outcomes of SPLM. Additionally, it offers insights into its future development prospects. SPLM clearly demonstrates advantages in minimizing surgical trauma and postoperative pain. However, it also confronts numerous technical hurdles. Substantially more evidence-based medical data is required to firmly establish its safety, feasibility, and long-term recurrence rate. Through a meticulous analysis of the current literature, further refinement of the technique, standardization of indication selection, and enhanced training of surgeons, SPLM is anticipated to emerge as a pivotal option in the surgical management of uterine fibroids. This will enable the provision of more personalized and patient-centric treatment alternatives for affected individuals.